Due to the proliferation of antibiotics and the careless disposal of these drugs into the environment, many drug-resistant strains of bacteria have started popping up. Aptly called Superbugs, these microorganisms have become such a major threat that scientists are now considering crazy solutions. Among them is to use viruses to kill the bacteria with the help of artificial intelligence.
As Futurism notes, the use of viruses to treat patients infected with Superbugs is often considered a last resort. Called bacteriophage or phage, previous methods have proven to be inaccurate, which made them less reliable than conventional medicine.
Unfortunately, the current state of bacterial infection has become desperate. That’s why companies like Adaptive Phage Therapeutics are coming up with better ways to analyze the genetic data of bacteria to match them with the right phage. This is where AI comes in since the data processing capabilities of machines can significantly shorten the amount of time needed to accomplish these tasks.
Speaking to MIT Review, Adaptive Phage Therapeutics CEO Greg Merril said that time is of the essence when Superbugs infect patients. Many of them don’t have the hours or days it takes to actually sequence the genetic code of bacteria and then match them with the right treatment.
“When a patient is critically ill, every minute is important,” Merril said.
At this point, these methods are still in their infancy and are nowhere near ready to be used on humans. Clinical trials are already underway, but the rate of the spread and growth of Superbugs might spur the government to focus on this issue sooner or later. Once even the most potent antibiotics are no longer able to treat what used to be minor infections, there are going to be a lot of deaths.
The drug companies haven’t exactly advanced that far in researching new drugs to fight bacteria over the last few decades.


Lab-grown meat: you may find it icky, but it could drive forward medical research
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Kennedy Sets September Deadline to Uncover Autism Causes Amid Controversy
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
ByteDance Unveils New AI Voice Assistant for ZTE Smartphones
Morgan Stanley Boosts Nvidia and Broadcom Targets as AI Demand Surges
Quantum Systems Projects Revenue Surge as It Eyes IPO or Private Sale
Apple Alerts EU Regulators That Apple Ads and Maps Meet DMA Gatekeeper Thresholds
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Apple Appoints Amar Subramanya as New Vice President of AI Amid Push to Accelerate Innovation
Apple Leads Singles’ Day Smartphone Sales as iPhone 17 Demand Surges 



